Summary & Overview
CPT 81439: Genomic Sequence Analysis Panel for Cardiomyopathy
CPT code 81439 represents a genomic sequence analysis panel targeting five to 49 genes relevant to various forms of cardiomyopathy. This advanced molecular diagnostic tool is increasingly important in the clinical management of inherited cardiac conditions, offering insights that can guide patient care and risk assessment. The code is recognized by major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, reflecting its broad adoption and coverage across the United States.
This publication provides a comprehensive overview of CPT 81439, including payer coverage, clinical context, and related coding benchmarks. Readers will gain an understanding of the procedure's role in pathology and laboratory medicine, typical laboratory settings, and its significance in diagnosing and managing cardiomyopathy. The summary also highlights associated ICD-10 diagnoses and related CPT codes, offering a clear picture of how this genomic panel fits within broader clinical and billing practices. Policy updates and coding nuances, such as common modifiers and provider taxonomies, are also discussed to inform stakeholders about current trends and requirements in medical billing for genomic sequencing procedures.
CPT Code Overview
CPT 81439 is used to report a genomic sequence analysis panel that evaluates five to 49 genes associated with cardiomyopathy, including conditions such as hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy. This procedure falls under Pathology and Laboratory Procedures, specifically Genomic Sequencing Procedures and Other Molecular Multianalyte Assays. The typical site of service for this test is a laboratory (POS 81).
Clinical & Coding Specifications
Clinical Context
A patient presents with symptoms suggestive of cardiomyopathy, such as shortness of breath, palpitations, or a family history of sudden cardiac death. The treating physician, often a clinical geneticist, family medicine physician, or internal medicine physician, orders a genomic sequence analysis panel to evaluate for genetic causes of cardiomyopathy. The laboratory receives the specimen and performs genomic sequencing targeting five to 49 genes associated with various forms of cardiomyopathy, including hypertrophic, dilated, and arrhythmogenic right ventricular cardiomyopathy. Results are interpreted and reported back to the ordering provider to inform diagnosis, prognosis, and potential management strategies.
Coding Specifications
-
Modifiers:
GX: Notice of Liability Issued, Voluntary Under Payer Policy. Used when a provider issues a notice to the patient that Medicare may not cover the service, but the notice is voluntary under payer policy.GY: Item or Service Statutorily Excluded, Does Not Meet the Definition of Any Medicare Benefit or, for Non‑Medicare Insurers, Is Not a Contract Benefit. Used when the service is excluded from coverage by Medicare or other payors.
-
Provider Taxonomies:
207SG0201X: Clinical Genetics (M.D.) — Physicians specializing in genetic disorders and testing.207Q00000X: Family Medicine Physician — Providers offering comprehensive care across all ages.